| Primary |
| Product Used For Unknown Indication |
21.7% |
| Torticollis |
16.9% |
| Muscle Spasticity |
11.4% |
| Hyperhidrosis |
9.8% |
| Blepharospasm |
7.1% |
| Skin Wrinkling |
5.7% |
| Migraine |
4.7% |
| Muscle Spasms |
3.1% |
| Pain |
3.1% |
| Dystonia |
3.0% |
| Facial Spasm |
2.6% |
| Headache |
2.2% |
| Back Pain |
1.2% |
| Cerebral Palsy |
1.2% |
| Gastrooesophageal Reflux Disease |
1.2% |
| Hypertension |
1.2% |
| Parkinson's Disease |
1.2% |
| Salivary Hypersecretion |
1.2% |
| Constipation |
0.8% |
| Hypothyroidism |
0.8% |
|
| Drug Ineffective |
38.2% |
| Eyelid Ptosis |
9.5% |
| Muscular Weakness |
7.5% |
| Dysphagia |
6.6% |
| Vision Blurred |
6.2% |
| Therapeutic Response Decreased |
5.8% |
| Injection Site Pain |
3.7% |
| Eyelid Oedema |
2.5% |
| Weight Decreased |
2.5% |
| Convulsion |
2.1% |
| Headache |
2.1% |
| Pain |
2.1% |
| Dyspnoea |
1.7% |
| Nausea |
1.7% |
| Wrong Technique In Drug Usage Process |
1.7% |
| Death |
1.2% |
| Fatigue |
1.2% |
| Guillain-barre Syndrome |
1.2% |
| Muscle Spasms |
1.2% |
| Musculoskeletal Stiffness |
1.2% |
|
| Secondary |
| Product Used For Unknown Indication |
17.4% |
| Muscle Spasticity |
14.1% |
| Torticollis |
13.1% |
| Pain |
10.6% |
| Myalgia |
5.4% |
| Blood Pressure |
4.2% |
| Depression |
4.2% |
| Gastrooesophageal Reflux Disease |
3.5% |
| Migraine |
3.5% |
| Constipation |
3.1% |
| Dystonia |
2.9% |
| Headache |
2.9% |
| Muscle Spasms |
2.7% |
| Muscle Tightness |
2.3% |
| Pain In Extremity |
2.3% |
| Back Pain |
2.1% |
| Blepharospasm |
1.5% |
| Hyperhidrosis |
1.5% |
| Facial Spasm |
1.4% |
| Gout |
1.2% |
|
| Weight Decreased |
13.9% |
| Drug Ineffective |
12.2% |
| Dysphonia |
9.6% |
| Eyelid Oedema |
6.1% |
| Dysphagia |
5.2% |
| Grand Mal Convulsion |
5.2% |
| Vision Blurred |
5.2% |
| Guillain-barre Syndrome |
4.3% |
| Therapeutic Response Decreased |
4.3% |
| Aphasia |
3.5% |
| Apnoea |
3.5% |
| Coronary Artery Thrombosis |
3.5% |
| Myopathy |
3.5% |
| Pneumonia |
3.5% |
| Tracheomalacia |
3.5% |
| Fatigue |
2.6% |
| Headache |
2.6% |
| Hypertension |
2.6% |
| Injection Site Pain |
2.6% |
| Injection Site Reaction |
2.6% |
|
| Concomitant |
| Dry Eye |
50.0% |
| Eyelid Disorder |
50.0% |
|
|
